{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:09:55Z","timestamp":1791266995711,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T00:00:00Z","timestamp":1415750400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00345-014-1439-6","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T15:30:48Z","timestamp":1415979048000},"page":"1281-1289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Arie","family":"Carneiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre Deeke","family":"Sasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Aurel","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Kataguiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ary Serpa","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Alves Vieira","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio Carlos Lima","family":"Pompeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tobias-Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,12]]},"reference":[{"issue":"6","key":"1439_CR1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0360-3016(88)90383-5","volume":"14","author":"GK Zagars","year":"1988","unstructured":"Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH (1988) Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14(6):1085\u20131091","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1439_CR2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2407-12-54","volume":"12","author":"AD Sasse","year":"2012","unstructured":"Sasse AD, Sasse E, Carvalho AM, Macedo LT (2012) Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review. BMC Cancer 12:54","journal-title":"BMC Cancer"},{"issue":"21","key":"1439_CR3","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A et al (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21):2359\u20132366","journal-title":"JAMA"},{"issue":"3 Suppl 1","key":"1439_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01560-1","volume":"60","author":"MV Meng","year":"2002","unstructured":"Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR (2002) Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60(3 Suppl 1):7\u201311","journal-title":"Urology"},{"issue":"11","key":"1439_CR5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","volume":"6","author":"JW Denham","year":"2005","unstructured":"Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S et al (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 6(11):841\u2013850","journal-title":"Lancet Oncol."},{"issue":"4","key":"1439_CR6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","volume":"54","author":"JA Efstathiou","year":"2008","unstructured":"Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54(4):816\u2013823","journal-title":"Eur Urol"},{"issue":"24","key":"1439_CR7","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","volume":"341","author":"EM Messing","year":"1999","unstructured":"Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341(24):1781\u20131788","journal-title":"N Engl J Med"},{"issue":"27","key":"1439_CR8","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448\u20134456","journal-title":"J Clin Oncol"},{"issue":"1","key":"1439_CR9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","volume":"15","author":"A Serpa Neto","year":"2012","unstructured":"Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL et al (2012) Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 15(1):36\u201344","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"1439_CR10","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/cncr.23970","volume":"113","author":"AV D\u2019Amico","year":"2008","unstructured":"D\u2019Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 113(12):3290\u20133297","journal-title":"Cancer"},{"issue":"20","key":"1439_CR11","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, D\u2019Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99(20):1516\u20131524","journal-title":"J Natl Cancer Inst"},{"key":"1439_CR12","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"issue":"7414","key":"1439_CR13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"3","key":"1439_CR14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"issue":"7304","key":"1439_CR15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","volume":"323","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323(7304):101\u2013105","journal-title":"BMJ"},{"issue":"5 Pt 1","key":"1439_CR16","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/01.ju.0000139719.99825.54","volume":"172","author":"P Iversen","year":"2004","unstructured":"Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P et al (2004) Bicalutamide (150\u00a0mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 172(5 Pt 1):1871\u20131876","journal-title":"J Urol"},{"issue":"2","key":"1439_CR17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.pcan.4500799","volume":"8","author":"M Wirth","year":"2005","unstructured":"Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM et al (2005) Bicalutamide (\u2018Casodex\u2019) 150\u00a0mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 8(2):194\u2013200","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"1439_CR18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/00365590601017329","volume":"40","author":"P Iversen","year":"2006","unstructured":"Iversen P, Johansson JE, Lodding P, Kylmala T, Lundmo P, Klarskov P et al (2006) Bicalutamide 150\u00a0mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 40(6):441\u2013452","journal-title":"Scand J Urol Nephrol"},{"issue":"12","key":"1439_CR19","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.2005.04.7423","volume":"24","author":"UE Studer","year":"2006","unstructured":"Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D et al (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24(12):1868\u20131876","journal-title":"J Clin Oncol"},{"issue":"1","key":"1439_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","volume":"27","author":"JA Efstathiou","year":"2009","unstructured":"Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27(1):92\u201399","journal-title":"J Clin Oncol"},{"issue":"11","key":"1439_CR21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"M Bolla","year":"2010","unstructured":"Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11(11):1066\u20131073","journal-title":"Lancet Oncol"},{"issue":"21","key":"1439_CR22","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","volume":"28","author":"M Hemelrijck Van","year":"2010","unstructured":"Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A et al (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol 28(21):3448\u20133456","journal-title":"J Clin Oncol"},{"issue":"26","key":"1439_CR23","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","volume":"29","author":"S Punnen","year":"2011","unstructured":"Punnen S, Cooperberg MR, Sadetsky N, Carroll PR (2011) Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29(26):3510\u20133516","journal-title":"J Clin Oncol"},{"issue":"8","key":"1439_CR24","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.09319.x","volume":"105","author":"P Iversen","year":"2010","unstructured":"Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP et al (2010) Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide early prostate cancer programme at a median follow-up of 9.7 years. BJU Int 105(8):1074\u20131081","journal-title":"BJU Int"},{"issue":"21","key":"1439_CR25","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","volume":"27","author":"SM Alibhai","year":"2009","unstructured":"Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM et al (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27(21):3452\u20133458","journal-title":"J Clin Oncol"},{"issue":"5","key":"1439_CR26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/00002512-200825050-00001","volume":"25","author":"D Kapoor","year":"2008","unstructured":"Kapoor D, Jones TH (2008) Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging 25(5):357\u2013369","journal-title":"Drugs Aging"},{"issue":"22","key":"1439_CR27","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1136\/hrt.2010.195412","volume":"96","author":"CJ Malkin","year":"2010","unstructured":"Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS (2010) Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96(22):1821\u20131825","journal-title":"Heart"},{"issue":"12","key":"1439_CR28","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","volume":"358","author":"MG Sanda","year":"2008","unstructured":"Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250\u20131261","journal-title":"N Engl J Med"},{"issue":"4","key":"1439_CR29","first-page":"465","volume":"166","author":"VB Shahinian","year":"2006","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2006) Risk of the \u201candrogen deprivation syndrome\u201d in men receiving androgen deprivation for prostate cancer. Arc Intern Med 166(4):465\u2013471","journal-title":"Arc Intern Med"},{"issue":"4","key":"1439_CR30","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","volume":"26","author":"M Roach 3rd","year":"2008","unstructured":"Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ et al (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26(4):585\u2013591","journal-title":"J Clin Oncol"},{"key":"1439_CR31","unstructured":"Network NCC. NCCN guidelines prostate cancer version 2.2013 2013 [cited 2013 05\/31\/2013]. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"issue":"3","key":"1439_CR32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/00365590801943274","volume":"42","author":"PO Hedlund","year":"2008","unstructured":"Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P et al (2008) Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 42(3):220\u2013229","journal-title":"Scand J Urol Nephrol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-014-1439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-014-1439-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-014-1439-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:40:17Z","timestamp":1559050817000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-014-1439-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,12]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1007\/s00345-014-1439-6","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,12]]}}}